ArticleJournal for immunotherapy of cancer2025

ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy.

Patrizia Murer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.